title: Expression of immune molecules CD25 and CXCL13 correlated with clinical severity of myasthenia gravis.
abstract: Differential expressions of immune molecules have been shown in the thymi with pathological results, including myasthenia gravis (MG). CD25 is an activation marker expressed on T cells. CXCL13 mediates the homing and motility of B cells in secondary lymphoid tissues. Herein, we investigated the expressions of CD25 and CXCL13 in the thymi of thymic hyperplasia patients with MG or with non-MG. A total of 34 thymic hyperplasia patients with MG (20 generalized MG (GMG) and 14 ocular MG (OMG) and six thymic hyperplasia patients without MG were enrolled and analyzed using immunohistochemical staining and real-time polymerase chain reaction for CD25 and CXCL13. Our study demonstrated a higher expression of both CD25 and CXCL13 in hyperplastic thymi with OMG or GMG compared to those with non-MG. According to the immunohistochemical results, we observed that CD25 expression was significantly lower in atrophic thymi and non-MG hyperplastic thymi, compared with that in infant thymi (P = 0.002 and 0.005, respectively). In contrast to CD25 expression, we did not observe differential expression of CXCL13 among three control groups. And a similar CD25 mRNA expression was found in real-time polymerase chain reaction (PCR) results. We observed that both hyperplastic thymi with OMG or GMG expressed significantly higher levels of CD25 than those with non-MG (P = 0.007 and 0.001, respectively). And an increase of CD25 expression was observed in hyperplastic thymi with GMG compared to those with OMG (P = 0.030). Similarly, CXCL13 expression was significantly higher in hyperplastic thymi with GMG or with OMG than those with non-MG (P = 0.001 and 0.050, respectively). No significant CXCL13 expression difference was found between hyperplastic thymi with GMG and those with OMG (P > 0.05). The real-time PCR results showed a similar tendency of CD25 mRNA expression among the thymi of non-MG, OMG, and GMG patients, but the difference did not reach significance (P > 0.05). An obvious increased expression of CXCL13 was found in hyperplastic thymi with GMG patients, compared to those with non-MG and OMG patients (P = 0.003 and 0.071, respectively). There was no difference found between hyperplastic thymi with non-MG and with OMG. Regression analysis showed a positive correlation between thymic CD25 level and MG symptom severity (F = 28.240; P = 0.000, r = 0.523). Similarly, a positive correlation was found between thymic CXCL13 expression and MG disease severity (F = 36.093; P = 0.000, r = 0.671). Taken together, our findings suggest CD25 and CXCL13 participate in the pathogenesis of MG and may influence the clinical symptoms of MG.
authors: Department of Neurology, Tangdu Hospital, Fourth Military Medical University, Xi'an, Shaanxi 710038, China.
authors: Min
authors: M
authors: Zhang
authors: Jun
authors: J
authors: Guo
authors: Hongzeng
authors: H
authors: Li
authors: Yongan
authors: Y
authors: Zhou
authors: Feng
authors: F
authors: Tian
authors: Li
authors: L
authors: Gong
authors: Xianni
authors: X
authors: Wang
authors: Zhuyi
authors: Z
authors: Li
authors: Wei
authors: W
authors: Zhang
mesh_terms: D000328:Adult; D016022:Case-Control Studies; D054382:Chemokine CXCL13 / Q000235:genetics / Q000378:metabolism; D005260:Female; D006801:Humans; D007223:Infant; D053645:Interleukin-2 Receptor alpha Subunit / Q000235:genetics / Q000378:metabolism; D008297:Male; D008875:Middle Aged; D009157:Myasthenia Gravis / Q000150:complications / Q000175:diagnosis* / Q000378:metabolism; D013950:Thymus Gland / Q000378:metabolism / Q000473:pathology; D013952:Thymus Hyperplasia / Q000150:complications / Q000175:diagnosis; D014158:Transcription, Genetic
chemical_list: C110663:CXCL13 protein, human; D054382:Chemokine CXCL13; C508017:IL2RA protein, human; D053645:Interleukin-2 Receptor alpha Subunit
references: Blood. 2003 Dec 1;102(12):4107-14
references: 12893750
references: J Neuroimmunol. 2002 Apr;125(1-2):185-97
references: 11960656
references: J Invest Dermatol. 2006 Mar;126(3):575-83
references: 16410787
references: J Neurol Neurosurg Psychiatry. 2007 Apr;78(4):386-90
references: 17088330
references: J Thorac Cardiovasc Surg. 2003 Dec;126(6):1922-8
references: 14688707
references: Clin Immunol. 2004 Sep;112(3):284-9
references: 15308122
references: Ann Neurol. 2010 May;67(5):625-38
references: 20437560
references: Tohoku J Exp Med. 2005 Oct;207(2):87-98
references: 16141677
references: Blood. 2006 Jul 15;108(2):432-40
references: 16543475
references: Scand J Immunol. 2004 Apr;59(4):408-14
references: 15049785
references: J Exp Med. 1998 Feb 16;187(4):655-60
references: 9463416
references: Rheumatology (Oxford). 2010 Nov;49(11):2084-9
references: 20693259
references: FASEB J. 2003 Feb;17(2):214-22
references: 12554700
references: J Exp Med. 2004 Apr 5;199(7):971-9
references: 15067033
references: Blood. 2007 May 15;109(10):4383-91
references: 17272501
references: Trends Mol Med. 2002 Oct;8(10):469-76
references: 12383769
references: Exp Gerontol. 2006 Apr;41(4):339-45
references: 16516426
references: Ann Thorac Surg. 2000 Jul;70(1):327-34
references: 10921745
references: Immunology. 2005 Sep;116(1):134-41
references: 16108825
references: Curr Opin Immunol. 2005 Oct;17(5):468-75
references: 16098723
references: Ann Neurol. 1983 Nov;14(5):516-9
references: 6651238
references: Blood. 2005 Jan 15;105(2):735-41
references: 15454488
references: Lancet. 2001 Jun 30;357(9274):2122-8
references: 11445126
references: Clin Immunol. 2003 Feb;106(2):116-26
references: 12672402
references: Nat Rev Genet. 2010 Sep;11(9):597-610
references: 20661255
references: J Exp Med. 2003 May 5;197(9):1191-8
references: 12732660
references: Nature. 2000 Jul 20;406(6793):309-14
references: 10917533
references: Gut. 2002 Sep;51(3):364-71
references: 12171958
references: J Neuroimmunol. 2010 Apr 15;221(1-2):101-6
references: 20223524
references: J Neurol Sci. 2012 Feb 15;313(1-2):27-31
references: 22000402